Go to deals
Soins de la Santé

Sapheon Inc. has been acquired by Covidien plc

Sapheon Inc., based in Santa Rosa, California, has been acquired by the Irish Covidien plc, a global healthcare products leader dedicated to innovation and long-term growth. Financial details have not been disclosed.

Sapheon Inc. is a medical device company whose mission is to develop new approaches and disruptive technologies for the treatment of vascular disease. The company’s current focus is the VenaSeal Sapheon Closure System, a novel treatment for venous reflux disease. Sapheon, Inc. will operate as a subsidiary of Covidien plc.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Through its Medical Devices and Medical Supplies segments, the company creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.

One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.

Services
Vente d'entreprise
Parties prenantes

Contacter l'équipe de la transaction

 Michael S. Goldman

Michael S. Goldman

Directeur général

New York, États-Unis
Oaklins TM Capital
 Andy  Krna

Andy Krna

Chef de la direction

New York, États-Unis
Oaklins TM Capital
 James  McLaren

James McLaren

Directeur général

New York, États-Unis
Oaklins TM Capital

Transactions connexes

Narva clinics has been acquired by Narva Åderbråckscenter AB
Soins de la Santé

Narva clinics has been acquired by Narva Åderbråckscenter AB

The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.

En apprendre plus
NS PARTNERS CO., LTD. has been acquired by JMDC Inc.
Soins de la Santé

NS PARTNERS CO., LTD. has been acquired by JMDC Inc.

Noritsu Koki Co., Ltd has sold NS PARTNERS CO., LTD. to JMDC Inc.

En apprendre plus
Protalix BioTherapeutics, Inc. has completed a private stock placement
Soins de la Santé

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

En apprendre plus